Floatz logo

BEBT 908

Relapsed or Refractory Non-Hodgkin's Lymphoma

BeBetter Med IncSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Relapsed or Refractory Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
BETAXOLOL
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2CCC
Bebt-908 For
BeBetter Med Inc
Phase 1CC

Same molecule, other indications

BEBT 908 is also rated in:

Relapsed or Refractory Diffuse Large B-cell LymphomaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
Relapsed or Refractory Multiple MyelomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →